Date: April 20, 2026

Tomocube, a leader in holotomography and label-free 3D live-cell imaging, today announced the appointment of  He Tong (何彤) as Sales Director for China. The appointment establishes dedicated regional leadership in Greater China as Tomocube expands access to holotomography across academic and biopharma markets in the region.

He Tong brings over 25 years of experience in life science instrumentation and biomedical imaging, having held commercial and leadership roles at PerkinElmer, GE Healthcare, and Sartorius. His background spans core imaging technologies, including spinning disk confocal microscopy, high-content screening systems, and in-vivo imaging systems, giving him a deep understanding of the evolving needs of both academic researchers and biopharmaceutical organizations in China.

“Holotomography technology holds significant application potential, spanning from cells and organoids to in vivo imaging. It indicates broad prospects for its use, from basic research to pharmaceutical R&D and clinical diagnostics,” says He Tong, sharing his enthusiasm for the technology that drew him to Tomocube.

He Tong emphasized that his decision to join the company reflects both the strength of Tomocube’s technology and the timing of its market opportunity. “The demand for advanced imaging tools in China continues to grow, particularly in pharmaceutical R&D and academic research. With one of the most comprehensive product portfolios in the industry, Tomocube is well-positioned to meet these needs. This is an exciting time to join the company.”

In his new role, He Tong will focus initially on expanding market awareness and strengthening distribution networks, particularly in central and western China. Key priorities include increasing engagement with academic institutions and introducing scalable solutions such as the HT-X1™ mini to serve a broader range of customers.

Looking ahead, his long-term vision includes building a local direct sales and technical support organization, as well as establishing a demonstration laboratory in a key city — reinforcing Tomocube’s long-term commitment to the Chinese market.

He Tong is also optimistic about the broader market environment. With 2026 marking the first year of China’s new Five-Year Plan, government investment in basic research and advanced therapeutics is increasing, while private-sector biopharma investment is accelerating. The Greater Bay Area, in particular, is emerging as a new hub for bioscience research — a region he sees as a significant opportunity for Tomocube.

“Cutting-edge technology, continuously evolving software, and the potential to expand into more application areas — this is what Tomocube brings to Chinese customers,” He Tong adds. His forward-looking perspective on the market reflects his leadership philosophy: open, responsible, and willing to make changes.

Sumin Lee, Senior Vice President of the Life Science Division at Tomocube, expressed her confidence in the appointment: “We are delighted to welcome He Tong to the Tomocube family. China is one of the most exciting and fast-moving life sciences markets in the world, and He Tong’s deep expertise in cell imaging technologies — combined with his strong understanding of both the academic and biopharma landscapes in China — makes him exceptionally well-suited to lead our growth in the region. We look forward to the impact he will make.”

---

About Tomocube, Inc.

Tomocube develops holotomography imaging systems for label-free 3D live-cell imaging. The company’s HT series platforms enable researchers to quantitatively visualize cells, organoids, and tissues without staining or fixation, supporting discovery in academic research, drug development, and clinical studies worldwide.

For media inquiries or further information, please contact:
info@tomocube.com
http://www.tomocube.com